154 related articles for article (PubMed ID: 22238151)
21. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/2nd communication: promising strategies].
Kuhlmann J
Arzneimittelforschung; 2004; 54(6):307-13. PubMed ID: 15282874
[TBL] [Abstract][Full Text] [Related]
22. Marker Sequential Test (MaST) design.
Freidlin B; Korn EL; Gray R
Clin Trials; 2014 Feb; 11(1):19-27. PubMed ID: 24085774
[TBL] [Abstract][Full Text] [Related]
23. Impacts on type I error rate with inappropriate use of learn and confirm in confirmatory adaptive design trials.
Wang SJ; James Hung HM; O'Neill RT
Biom J; 2010 Dec; 52(6):798-810. PubMed ID: 21154897
[TBL] [Abstract][Full Text] [Related]
24. [Meta-analysis of the Italian studies on short-term effects of air pollution].
Biggeri A; Bellini P; Terracini B;
Epidemiol Prev; 2001; 25(2 Suppl):1-71. PubMed ID: 11515188
[TBL] [Abstract][Full Text] [Related]
25. Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials.
Renfro LA; Shi Q; Sargent DJ; Carlin BP
Stat Med; 2012 Apr; 31(8):743-61. PubMed ID: 22161275
[TBL] [Abstract][Full Text] [Related]
26. A Bayesian predictive strategy for an adaptive two-stage design in phase II clinical trials.
Sambucini V
Stat Med; 2010 Jun; 29(13):1430-42. PubMed ID: 20099246
[TBL] [Abstract][Full Text] [Related]
27. The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation.
Nixon RM; O'Hagan A; Oakley J; Madan J; Stevens JW; Bansback N; Brennan A
Pharm Stat; 2009; 8(4):371-89. PubMed ID: 19340851
[TBL] [Abstract][Full Text] [Related]
28. Evaluating and utilizing probability of study success in clinical development.
Wang Y; Fu H; Kulkarni P; Kaiser C
Clin Trials; 2013; 10(3):407-13. PubMed ID: 23471634
[TBL] [Abstract][Full Text] [Related]
29. Bayesian design and analysis of two x two factorial clinical trials.
Simon R; Freedman LS
Biometrics; 1997 Jun; 53(2):456-64. PubMed ID: 9192445
[TBL] [Abstract][Full Text] [Related]
30. Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress.
Garcia VM; Cassier PA; de Bono J
Cancer Discov; 2011 Aug; 1(3):207-12. PubMed ID: 22586572
[TBL] [Abstract][Full Text] [Related]
31. From trial and error to trial simulation III: a framework for interim analysis in efficacy trials with antidepressant drugs.
Santen G; van Zwet E; Bettica P; Gomeni RA; Danhof M; Della Pasqua O
Clin Pharmacol Ther; 2011 Apr; 89(4):602-7. PubMed ID: 21368749
[TBL] [Abstract][Full Text] [Related]
32. A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables.
Jiang Z; Song Y; Shou Q; Xia J; Wang W
Trials; 2014 Dec; 15():500. PubMed ID: 25528466
[TBL] [Abstract][Full Text] [Related]
33. Clinical trials for predictive medicine.
Simon R
Stat Med; 2012 Nov; 31(25):3031-40. PubMed ID: 22714719
[TBL] [Abstract][Full Text] [Related]
34. Improving the outcomes: developing cancer therapeutics.
Utku N
Future Oncol; 2012 Jan; 8(1):87-103. PubMed ID: 22149037
[TBL] [Abstract][Full Text] [Related]
35. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
36. A two-stage patient enrichment adaptive design in phase II oncology trials.
Song JX
Contemp Clin Trials; 2014 Jan; 37(1):148-54. PubMed ID: 24342820
[TBL] [Abstract][Full Text] [Related]
37. Statistical inference on censored data for targeted clinical trials under enrichment design.
Chen CF; Lin JR; Liu JP
Pharm Stat; 2013; 12(3):165-73. PubMed ID: 23606647
[TBL] [Abstract][Full Text] [Related]
38. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/1st communication: The contribution of clinical pharmacology].
Kuhlmann J
Arzneimittelforschung; 2004; 54(5):251-8. PubMed ID: 15212186
[TBL] [Abstract][Full Text] [Related]
39. Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer.
Royston P; Parmar MK; Qian W
Stat Med; 2003 Jul; 22(14):2239-56. PubMed ID: 12854091
[TBL] [Abstract][Full Text] [Related]
40. Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling.
Gieschke R; Reigner BG; Steimer JL
Int J Clin Pharmacol Ther; 1997 Oct; 35(10):469-74. PubMed ID: 9352398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
